Clinical Trials Update provides you with latest news about clinical trials conducted by companies located in Medicon Valley and gives insight to progress in studies, results and possible indications. 

Probi AB Proceed With Bacteria Research Against the Cold

4 February - Trials in Lund and Uppsala last spring showed that the bacteria that are being developed also have an effect on the cold. Probi now continues with a 300 person trial in Berlin and expect to have a product on the market by 2009.

Read more (in Danish)

Biovitrum and Symphogen have Completed Phase I Clinical Trial

6 February - Biovitrum and Symphogen are developing a recombinant, polyclonal antibody (Sym001) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and prophylaxis of hemolytic disease of the newborn. The phase I clinical trial was initiated in March 2007 and the results from the study show that Sym001 is safe and well tolerated.

Altogether 59 RhD-positive (to support further studies in ITP) and 18 RhD-negative (to support further studies in ADP) healthy male volunteers were enrolled in the double-blind1, randomized2, placebo-controlled3, dose-escalation phase I trial. The trial was conducted at a phase I unit in the United States.

Symphogen and Biovitrum are jointly developing Sym001 under a co-development and commercialization agreement announced in February 2006.

Read more